Importance of C-Reactive Protein Level in Predicting Non-Response to Additional Intravenous Immunoglobulin Treatment in Children with Kawasaki Disease

[1]  S. Kurotobi,et al.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment , 2006, European Journal of Pediatrics.

[2]  T. Matsuishi,et al.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. , 2006, The Journal of pediatrics.

[3]  Tomio Kobayashi,et al.  Prediction of Intravenous Immunoglobulin Unresponsiveness in Patients With Kawasaki Disease , 2006, Circulation.

[4]  J. Furui,et al.  Risk factors associated with the need for additional intravenous gamma‐globulin therapy for Kawasaki disease , 2006, Acta paediatrica.

[5]  Yoshikazu Nakamura,et al.  Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition) , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[6]  S. Ito,et al.  Plasma exchange for refractory Kawasaki disease , 2004, European Journal of Pediatrics.

[7]  M. Al-Azri,et al.  Kawasaki disease resistant to immunoglobulin G therapy , 2003, Annals of tropical paediatrics.

[8]  K. Durongpisitkul,et al.  Immunoglobulin Failure and Retreatment in Kawasaki Disease , 2003, Pediatric Cardiology.

[9]  M. Ishii,et al.  Re‐treatment for immune globulin‐resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy , 2001, Pediatrics international : official journal of the Japan Pediatric Society.

[10]  T. Onodera,et al.  Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. , 2000, The Journal of pediatrics.

[11]  J. Newburger,et al.  Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. , 1998, The Pediatric infectious disease journal.

[12]  K. Waki,et al.  Coronary risk factors in acute Kawasaki disease: Correlation of serum immunoglobulin levels with coronary complications , 1998, Acta paediatrica Japonica : Overseas edition.

[13]  J. Newburger,et al.  A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. , 1998, The American journal of cardiology.

[14]  K. Shiraki,et al.  Normal levels of IgG subclass in childhood determined by a sensitive ELISA , 1993, Acta paediatrica Japonica : Overseas edition.

[15]  M Takahashi,et al.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. , 1991, The New England journal of medicine.

[16]  S. Daniels,et al.  Coronary artery caliber in normal children and patients with Kawasaki disease but without aneurysms: an echocardiographic and angiographic study. , 1986, Journal of the American College of Cardiology.

[17]  H. Nakano,et al.  Scoring method for identifying patients with Kawasaki disease at high risk of coronary artery aneurysms. , 1986, The American journal of cardiology.

[18]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[19]  H. Kato,et al.  Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. , 1986, The Journal of pediatrics.

[20]  H. Nakano,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[21]  D. Morens,et al.  National surveillance of Kawasaki disease. , 1980, Pediatrics.

[22]  T. Ohzeki,et al.  Ulinastatin Therapy in Kawasaki Disease , 2007, Clinical drug investigation.

[23]  J. Newburger,et al.  Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. , 1996, The Journal of pediatrics.

[24]  M. Iwasa,et al.  Selection of high-risk children for immunoglobulin therapy in Kawasaki disease. , 1987, Progress in clinical and biological research.